These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30929580)

  • 1. Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA.
    Baselyous Y; De Cocinis M; Ibrahim M; Kalra A; Yacoub R; Ahmed R
    Expert Opin Drug Saf; 2019 Mar; 18(3):153-161. PubMed ID: 30929580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran.
    McDonald CJ; Kalisch Ellett LM; Barratt JD; Caughey GE
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):399-405. PubMed ID: 24841749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cross-country comparison of rivaroxaban spontaneous adverse event reports and concomitant medicine use with the potential to increase the risk of harm.
    McDonald CJ; Kalisch Ellett LM; Barratt JD; Caughey GE
    Drug Saf; 2014 Dec; 37(12):1029-35. PubMed ID: 25361529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal failure associated with the use of celecoxib and rofecoxib.
    Ahmad SR; Kortepeter C; Brinker A; Chen M; Beitz J
    Drug Saf; 2002; 25(7):537-44. PubMed ID: 12093311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
    Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans.
    Roughead EE; Ramsay E; Pratt N; Gilbert AL
    Drug Saf; 2008; 31(11):997-1003. PubMed ID: 18840019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy.
    Knudsen JF; Sokol GH; Flowers CM
    J Clin Pharm Ther; 2008 Oct; 33(5):513-9. PubMed ID: 18834366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for linezolid-related blindness: a review of spontaneous adverse event reports.
    Brown J; Aitken SL; van Manen RP
    Pharmacotherapy; 2011 Jun; 31(6):585-90. PubMed ID: 21923442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database.
    Khadem TM; van Manen RP; Brown J
    Pharmacotherapy; 2014 Dec; 34(12):1324-9. PubMed ID: 25421400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
    De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
    Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
    Durrieu G; Olivier P; Montastruc JL;
    Eur J Clin Pharmacol; 2005 Sep; 61(8):611-4. PubMed ID: 16133552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.
    Hochberg AM; Pearson RK; O'Hara DJ; Reisinger SJ
    Drug Saf; 2009; 32(2):137-46. PubMed ID: 19236120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.
    Sakaeda T; Kadoyama K; Okuno Y
    Int J Med Sci; 2011; 8(6):487-91. PubMed ID: 21897761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.